Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Chemotherapy for hematologic malignancy

PreclinicalSmall molecule

MM.D. Anderson Cancer Center

Chemotherapy for hematologic malignancy is one of 2 small molecule programs targeting IUD. It is currently in Preclinical.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

IUDCompleted

IUDPreclinical

Completed

Competition

Competitive Landscape

1 competitor in IUD

#DrugCompanyPhaseTrials

Penthrane

PPurdue Pharma, Canada

Chemotherapy for hematologic malignancy

MM.D. Anderson Cancer Center

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

IUD1 trial

IUdR/BUdR Cell Cycle Labelling

Completed·MM.D. Anderson Cancer Center·N/A·NCT00042250·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Chemotherapy for hematologic malignancy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Chemotherapy for hematologic malignancy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Chemotherapy for hematologic malignancy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — M.D. Anderson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MM.D. Anderson Cancer Center

Related News